Sign in →

Test Code BCRAB BCR::ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies


Ordering Guidance


This test is intended for monitoring patients with known e13/a2 or e14/a2 BCR::ABL1 (p210) fusion forms.

 

This test should not be used to screen for BCR::ABL1 fusions at the time of diagnosis.

 

To screen for BCR::ABL1 fusions at the time of diagnosis, order one of the following:

-BADX / BCR::ABL1, Qualitative, Diagnostic Assay, Varies

-BCRFX / BCR::ABL1 Qualitative Diagnostic Assay with Reflex to BCR::ABL1 p190 Quantitative Assay or BCR::ABL1 p210 Quantitative Assay, Varies .

 

To monitor patients carrying BCR::ABL1 fusion forms coding for the p190 (e1/a2) protein, order BA190 / BCR::ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.

 

To monitor patients carrying rare BCR::ABL1 fusion forms coding for e19a2, e13/e14a3, e1a3, e6a2, e19a3, e8a2, e12a2, e6a3, e8a3, and e12a3, order BARQ / BCR::ABL1, Rare Fusion Monitoring, Quantitative, Varies.

 

If the patient has a negative history for p210 but has positive history of p190 or a rare fusion form, this test will be cancelled, and one of the following appropriate monitoring tests will be added:

-BA190 / BCR::ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies

-BARQ / BCR::ABL1, Rare Fusion Monitoring, Quantitative, Varies



Shipping Instructions


Specimen must arrive within 3 days (72 hours) of collection. Collect and package specimen as close to shipping time as possible.



Necessary Information


Pertinent clinical history including if the patient has a diagnosis of chronic myeloid leukemia or other BCR::ABL1-positive neoplasm information is required.



Specimen Required


Submit only 1 of the following specimens:

 

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 10 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

3. Label specimen as whole blood.

 

Specimen Type: Bone marrow

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix bone marrow.

2. Send bone marrow specimen in original tube. Do not aliquot.

3. Label specimen as bone marrow.


Forms

1. Hematopathology Patient Information (T676)

2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.

Secondary ID

89007

Useful For

Monitoring response to therapy in patients with chronic myeloid leukemia who are known to have e13/a2 or e14/a2 BCR::ABL1 fusion transcript forms

Testing Algorithm

For information see BCR/ABL1 Ordering Guide for Blood and Bone Marrow.

Method Name

Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Reporting Name

BCR/ABL1, p210, Quant, Monitor

Specimen Type

Varies

Specimen Minimum Volume

Whole blood: 4 mL; Bone marrow: 1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Refrigerated (preferred) 72 hours PURPLE OR PINK TOP/EDTA
  Ambient  72 hours PURPLE OR PINK TOP/EDTA

Reject Due To

Gross hemolysis Reject
Moderately to severely clotted Reject

Reference Values

The presence or absence of BCR::ABL1 messenger RNA (mRNA) fusion form e13/e14-a2 producing the p210 fusion protein is identified. If positive, the quantitative level is reported as the normalized ratio of BCR::ABL1 (p210) to endogenous ABL1 mRNA with conversion to a percentage referenced to the international scale (IS), on which 0.1% BCR::ABL1:ABL1 (also represented on a log scale as Molecular Response 3, or MR3) is designated as a major molecular response (MMR) threshold.

Day(s) Performed

Monday through Saturday

Report Available

3 to 6 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81206

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BCRAB BCR/ABL1, p210, Quant, Monitor 55135-8

 

Result ID Test Result Name Result LOINC Value
48411 BCR/ABL1, p210 Result 55135-8
MP003 Specimen Type 31208-2
19598 Final Diagnosis: 34574-4